Q3 EPS Estimates for Cosmos Health Cut by Zacks Research

Cosmos Health Inc. (NASDAQ:COSM) – Equities research analysts at Zacks Research cut their Q3 2026 earnings per share (EPS) estimates for Cosmos Health in a report released on Wednesday, August 19th. Zacks Research analyst B. Sorensen now forecasts that the company will post earnings of ($0.05) per share for the quarter, down from their prior forecast of $0.02. The consensus estimate for Cosmos Health’s current full-year earnings is $0.01 per share. Zacks Research also issued estimates for Cosmos Health’s Q4 2026 earnings at ($0.03) EPS and FY2026 earnings at ($0.21) EPS.

Cosmos Health (NASDAQ:COSM) last released its quarterly earnings data on Tuesday, August 18th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.11). Cosmos Health had a negative net margin of 33.08% and a negative return on equity of 56.88%. The business had revenue of $19.32 million during the quarter, compared to analyst estimates of $18.99 million.

Separately, Weiss Ratings raised shares of Cosmos Health from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, July 30th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, Cosmos Health currently has a consensus rating of “Sell”.

Cosmos Health Stock Up 8.8%

COSM stock opened at $0.21 on Friday. Cosmos Health has a 1-year low of $0.16 and a 1-year high of $1.32. The business’s 50 day simple moving average is $0.22 and its 200 day simple moving average is $0.30. The company has a current ratio of 1.05, a quick ratio of 0.92 and a debt-to-equity ratio of 0.15. The firm has a market capitalization of $12.61 million, a PE ratio of -0.33 and a beta of 4.80.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in shares of Cosmos Health during the second quarter worth $49,000. XTX Topco Ltd grew its stake in shares of Cosmos Health by 52.1% in the fourth quarter. XTX Topco Ltd now owns 99,610 shares of the company’s stock valued at $50,000 after acquiring an additional 34,117 shares in the last quarter. Renaissance Technologies LLC increased its position in Cosmos Health by 16.7% during the first quarter. Renaissance Technologies LLC now owns 390,500 shares of the company’s stock worth $124,000 after acquiring an additional 55,925 shares during the period. Finally, Citadel Advisors LLC increased its position in Cosmos Health by 133.1% during the third quarter. Citadel Advisors LLC now owns 225,507 shares of the company’s stock worth $250,000 after acquiring an additional 128,776 shares during the period. Institutional investors own 12.61% of the company’s stock.

Insider Activity at Cosmos Health

In other news, CFO Georgios Terzis acquired 168,135 shares of Cosmos Health stock in a transaction dated Tuesday, June 16th. The stock was bought at an average price of $0.25 per share, for a total transaction of $42,033.75. Following the completion of the acquisition, the chief financial officer directly owned 2,235,398 shares in the company, valued at approximately $558,849.50. The trade was a 8.13% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Grigorios Siokas bought 349,825 shares of the firm’s stock in a transaction dated Thursday, July 30th. The stock was purchased at an average cost of $0.20 per share, for a total transaction of $69,965.00. Following the transaction, the chief executive officer directly owned 14,597,917 shares of the company’s stock, valued at $2,919,583.40. The trade was a 2.46% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 2,204,138 shares of company stock valued at $457,137 over the last 90 days. Company insiders own 26.15% of the company’s stock.

Cosmos Health Company Profile

Cosmos Health Inc manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors.